TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03550313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: Pneumococcal conjugate vaccine
Study: NCT02936557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)
Study: NCT01297062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: IV Exenatide (therapeutic and supratherapeutic concentrations)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Oral Moxifloxacin (400 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: IV Placebo (matching volume of placebo)
Study: NCT03846700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aquablation
Description: minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: holep
Description: holmium laser enucleation of prostate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pvp
Description: photoselectivevaporization of prostate
Study: NCT00160433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 0.5 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 1.5 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5.0 mg Tablet, oral Daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 weeks
Study: NCT00622167

Intervention type: DEVICE
Group type: OTHER
Intervention: Integrated Backscatter IVUS
Description: All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual Source Computed Tomography
Description: All subjects have DSCT and IBIVUS imaging
Study: NCT03463902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left IFG anodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left IFG cathodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left IPL anodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left IPL cathodal
Description: Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
Study: NCT02818881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed yoga

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed yoga

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-speed yoga

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-speed yoga
Study: NCT03034148

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Platelet Acetyl Coenzyme A Carboxylase analysis in CAD
Study: NCT02676869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP321 (eftilagimod alpha)
Description: Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered according to the approved label.
Study: NCT03336619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide 600 mg administered orally twice daily for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally twice daily for five days
Study: NCT01446458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Description: Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
Study: NCT02370706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: JAK1/JAK2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: CDK4/6 inhibitor
Study: NCT03555370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Exercise Intervention
Description: The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
Study: NCT04843085

Intervention type: OTHER
Intervention: Proteomic analysis
Description: : Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples

Intervention type: OTHER
Intervention: Proteomic analysis
Description: : Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples

Intervention type: OTHER
Intervention: Proteomic analysis
Description: : Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples

Intervention type: OTHER
Intervention: Proteomic analysis
Description: : Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples

Intervention type: OTHER
Intervention: Proteomic analysis
Description: : Proteomic analysis in the 3 subgroups of oligodendrogliomas (O1, O2 and O3) and in the comparator groups of IDH-mutant astrocytomas, IDH-wildtype glioblastomas and normal brain samples
Study: NCT05773690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement quality
Description: 6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing mobility, stability and motor control exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Resistance Training
Description: 6-week-home-based training protocols designed to improve general fitness levels and postural control performed in a circuit-training mode (time of work per set 30 s, time of rest between each exercise 15 s, time of rest between sets 2 min, total volume 3 sets) for a duration of 45 min with a frequency of 3 days per week while performing traditional strength training exercises
Study: NCT02625766

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC fracture surgical fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LC fracture non-operative management
Study: NCT03704779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal mindfulness activity program
Description: This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations.
Study: NCT02352740

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A form Arginine
Description: 3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A form Arginine
Description: 3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B form Arginine
Description: 3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B form Arginine
Description: 3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
Study: NCT02684500

Intervention type: DEVICE
Intervention: Ultrasound
Description: Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
Study: NCT03978871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth Mindset
Description: Growth emotion mindset induction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Brain education
Study: NCT00325533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline BP Screening
Description: Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive 10-week Blood Pressure Screening
Description: Intensive 10-week Blood Pressure Screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive 10-week Blood Pressure Screening
Description: Intensive 10-week Blood Pressure Screening
Study: NCT03640936

Intervention type: BEHAVIORAL
Intervention: Induced Sputum
Description: Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum

Intervention type: BEHAVIORAL
Intervention: Induced Sputum
Description: Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum

Intervention type: BEHAVIORAL
Intervention: Induced Sputum
Description: Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
Study: NCT01664195

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Alfa
Description: Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.

Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Alfa
Description: Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
Study: NCT01654146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC5 by intravenous infusion over 30-60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 by intravenous infusion over 30-60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC2 by intravenous infusion over 30-60 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175mg/m2 by intravenous infusion over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 by intravenous infusion over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80mg/m2 by intravenous infusion over 1 hour
Study: NCT01840956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAVG
Description: HAVG is implanted into patients' arm.
Study: NCT03569319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK-MED resource (baseline)
Description: The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK-MED resource (staged)
Description: This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention).
Study: NCT02006966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic intravenous lidocaine infusion
Description: In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline infusion
Description: In group C, the patients receive same volume of normal saline
Study: NCT03369756

Intervention type: DEVICE
Group type: OTHER
Intervention: Prontosan Wound Irrigation Solution and Prontosan Wound Gel
Description: Wound cleansing using Prontosan solution and gel
Study: NCT00095290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril + Irbesartan
Description: Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramipril + Placebo
Description: Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
Study: NCT06720233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAL-0951 tablets
Description: initial phase：4mg QD subsequent phase：1mg～8mg QD，adjust the dose based on hemoglobin concentration level every 4 weeks
Study: NCT01573832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated client care group
Description: receives integrated client care for wound treatment
Study: NCT03846921

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory blood test
Description: Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory blood test
Description: Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
Study: NCT00936377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
Study: NCT00936377

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for five days.
Study: NCT02189694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop strategy
Description: Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop strategy
Description: Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump therapy
Description: Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
Study: NCT01723956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
Study: NCT04360148

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: very-low-calorie-ketogenic-diet
Description: VLCKD-group will undergone to VLCKD for 8 weeks. VLCKD is based on protein preparations of high biological value. Total daily energy intake is \< 800 kcal.Daily carbohydrate intake is lower than 30 g/day, while daily protein intake is approximately 1.2-1.5 g/kg of ideal body weight. The following four weeks, carbohydrates are gradually reintroduced, starting from foods with the lowest glycemic index (fruit, dairy products), followed by foods with moderate and high glycemic index (bread, pasta and cereals). The goal is to achieve a hypocaloric balanced diet (HBD), as well as the controlled group. From the 12th week to the 24 th week, all subjects enrolled will continue follow-up with HBD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric-balanced-diet
Description: HBD-group will undergone to hypo caloric balanced diet for 24 weeks. Total daily average energy intake is 1500-1600 kcal/day. 30% of total daily energy is composed by lipids (10% MUFA, 10% PUFA, 10% SFA), 55% carbohydrates, while daily protein intake is approximately 0.8-1.5 g /kg of ideal body weight.
Study: NCT01723956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP
Description: The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
Study: NCT01521728

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Exercise
Description: Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/Range-of-Motion
Description: Stretching and range of motion exercise is widely accepted as a standard of care for ALS management.